Abstract

A major obstacle to the development of medications for nicotine dependence is the lack of animal and human laboratory models with sufficient predictive clinical validity to support the translation of knowledge from laboratory studies to clinical research. This Review describes the animal and human laboratory paradigms commonly used to investigate the pathophysiology of nicotine dependence, and proposes how their predictive validity might be determined and improved, thereby enhancing the development of new medications.

Author affiliations

1. Department of Psychiatry and Abramson Cancer Center, University of Pennsylvania, 3535 Market Street, Suite 4100, Philadelphia, Pennsylvania 19104, USA.
2. Minneapolis Medical Research Foundation, 914 South 8^th Street, Minneapolis, Minnesota 55404, USA.
3. WPIC University of Pittsburgh, 3811 O'Hara Street, Pittsburgh, Pennsylvania 15213, USA.
4. Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, Connecticut 06519, USA.
5. Department of Psychiatry, Translational Research Laboratories, Room 2223 University of Pennsylvania, 125 South 31^st Street, Philadelphia, Pennsylvania 19104, USA.
6. Department of Medicine, University of California San Francisco, BOX 1220, San Francisco, California 94110, USA.
7. Department of Psychiatry, University of Minnesota, F282/2A West, 2450 Riverside Avenue South Minneapolis, Minnesota 55454, USA.

Correspondence to: Caryn Lerman¹ Email: clerman@mail.med.upenn.edu

Correspondence to: William A. Corrigall^2,7 Email: corri040@umn.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.